Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 0.55 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2995309 | 0.89 | P2RX7 (0.54) | P2RX7ANO1ALDH1A1 | |
| SCHEMBL2995172 | 0.84 | P2RX7 (0.44) | P2RX7ANO1 | |
| SCHEMBL2998985 | 0.84 | P2RX7 (0.79) | P2RX7 | |
| SCHEMBL2998992 | 0.84 | P2RX7 (0.79) | P2RX7 | |
| SCHEMBL3006015 | 0.83 | P2RX7 (0.57) | P2RX7KMT2AALDH1A1 | |
| SCHEMBL3010634 | 0.83 | P2RX7 (0.57) | P2RX7KMT2AALDH1A1 | |
| SCHEMBL4141045 | 0.81 | P2RX7 (0.48) | P2RX7ANO1ALDH1A1MAPT | |
| SCHEMBL8233898 | 0.76 | P2RX7 (0.47) | P2RX7KMT2AALDH1A1 | |
| SCHEMBL3015968 | 0.76 | P2RX7 (0.39) | P2RX7 | |
| SCHEMBL13243837 | 0.76 | P2RX7 (0.72) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184802-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184802-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885ANO1 1352/4885KMT2A 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.